New Zealand markets closed
  • NZX 50

    12,066.79
    -73.87 (-0.61%)
     
  • NZD/USD

    0.7344
    -0.0030 (-0.41%)
     
  • NZD/EUR

    0.6050
    +0.0003 (+0.06%)
     
  • ALL ORDS

    7,105.70
    +56.30 (+0.80%)
     
  • ASX 200

    6,834.00
    +56.20 (+0.83%)
     
  • OIL

    62.89
    -0.64 (-1.01%)
     
  • GOLD

    1,755.00
    -20.40 (-1.15%)
     
  • NASDAQ

    12,828.31
    0.00 (0.00%)
     
  • FTSE

    6,651.96
    -7.01 (-0.11%)
     
  • Dow Jones

    31,402.01
    -559.85 (-1.75%)
     
  • DAX

    13,879.33
    -96.67 (-0.69%)
     
  • Hang Seng

    29,098.24
    -975.93 (-3.25%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • NZD/JPY

    77.8720
    -0.3980 (-0.51%)
     

Global Colorectal Cancer Diagnostics and Therapeutics Market 2020-2025 with Abbott Laboratories, Epigenomics, F. Hoffmann-La Roche, Novigenix, and Siemens Healthineers Dominating - ResearchAndMarkets.com

·3-min read

The "Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The colorectal cancer diagnostics and therapeutics market is expected to register a CAGR of nearly 4.6% during the forecast period.

Colorectal cancer has one of the largest incidence and prevalence rates, worldwide. Primary causes of colorectal cancer are said to be lifestyle disorders, ageing, and diet.

According to the World Health Organization (WHO), an increase of around 70% is expected in the colorectal cancer cases across the world, by 2030. Therefore, high incidence and prevalence rates are the primary factors, driving the market studied.

According to a research article published in 2016, "Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the United States."

Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and is a major cause of morbidity and mortality throughout the world. CRC is the second-most-common cause of cancer-related deaths in the United States.

Key Market Trends

Immunotherapy Expected to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.

Immunotherapy refers to the fighting cancer cells by taking advantage of the human immune system. There are several immunotherapy drugs available for colorectal cancer worldwide. These therapeutics include targeted antibodies and checkpoint inhibitors.

  • Furthermore, growing R&D on combination therapy coupled with rising awareness on cancer therapeutics and advantages of immunotherapy anticipated fueling the segment growth over the forecast period.

  • For instance, in August 2018, United States Food and Drug Administration approved combination of immunotherapeutic drugs ipilimumab (Yervoy) and nivolumab (Opdivo) for the treatment of some patients with metastatic colorectal cancer who have been treated previously with standard chemotherapy drugs.

  • Moreover, the expansion of therapeutic applications of immunotherapeutic agents to colorectal cancer is projected to further fuel the market growth.

United States is Expected to Retain Largest Market Share During the Forecast Period

Geographically, the North America colorectal cancer diagnostics and therapeutics market projected to have significant market share with respect to demand and revenue.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics by launching new products participating in collaborations and acquisitions.

Key players in the market include Abbott Laboratories, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, and Siemens Healthineers among others.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Technological Advancements in Radiology and Chemotherapy

4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer

4.3 Market Restraints

4.3.1 High Costs and the Side Effects Associated with Drugs

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Modality

5.1.1 Diagnostics Techniques

5.1.1.1 Stool Tests

5.1.1.2 Immunohistochemistry

5.1.1.3 Colonoscopy

5.1.1.4 Flexible Sigmoidoscopy

5.1.1.5 Other Diagnostics Techniques

5.1.2 Therapeutics

5.1.2.1 Chemotherapy

5.1.2.2 Immunotherapy

5.1.2.3 Others

5.2 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 Amgen Inc.

6.1.3 Clinical Genomics

6.1.4 EDP Biotech

6.1.5 Epigenomics AG

6.1.6 F. Hoffmann-La Roche AG

6.1.7 Novigenix SA

6.1.8 Quest Diagnostics

6.1.9 Sanofi SA

6.1.10 Siemens Healthineers

6.1.11 VolitionRX

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/zcvsil

View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005348/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900